RxDoctor Payments Data

Robert Salata, MD

Infectious Disease · Cleveland, OHNPI 1649290297

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,170 of the $2,534 with a category attached, or 85.6%. Pfizer accounts for 88.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $2,266 and has fallen 92.5% since, to $171 in 2023.

$2,534in general payments, 2019–2025

Across 11 payments — averaging $230.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Elekta, Inc.$127
  • Ferring Pharmaceuticals Inc.$76
  • Gilead$46
  • AbbVie$18
  • Tetraphase Pharmaceuticals, Inc.$16
$2,830,568in research payments, 2019–2025

Across 241 payments — averaging $11,745 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.7M
  • Janssen Research & Development, LLC$97K
  • Shionogi Inc$20K

What the payments were for

  • Consulting fees$2,17086%
  • Travel & lodging$622%
  • Food & beverage$2078%
  • Education$763%
  • Gifts$201%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,534 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$3,360
Medicare patients
12
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala116$488,386
TriumeqAbacavir/Dolutegravir/Lamivudi32$146,565
TivicayDolutegravir Sodium18$58,193
IsentressRaltegravir Potassium19$49,010
Etravirine22$30,855
PifeltroDoravirine11$19,033
Darunavir11$9,396
Tenofovir Disoproxil Fumarate12$2,588
Ritonavir18$1,583
Omeprazole33$538
Dapsone11$455
Doxycycline Hyclate13$394
Gabapentin44$288
Atorvastatin Calcium76$285
Duloxetine Hcl13$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$46$488,386116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →